Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Amarin's Stock Drops on Plan to Sell Heart Drug Vascepa Alone


Investors hoped the drug maker would find a buyer or at least a marketing partner for launch of drug derived from pure fish oil.

MINYANVILLE ORIGINAL Shares of Amarin (NASDAQ:AMRN) are falling after the drug maker said it will hire a sales force to market its heart medicine derived from pure fish oil rather than partner with another company. Amarin says it is still exploring a strategic partner or outright sale of the company.

Amarin says it will hire as many as 300 sales representatives to launch the drug Vascepa in the US during the first quarter of 2013. The announcement, made late in the day Thursday, also detailed a $100 million financing the company arranged through an investment fund.

The company's shares dropped 20% to $9.60 in early trading Friday. The stock is down by more than a third in the past three months.

The company is awaiting a decision from US officials on market exclusivity for the drug, a treatment that's more potent than over-the-counter fish oil products. Vascepa aims to lower triglycerides, a type of fat, in blood.

(See also: Investors Still Waiting for Decision on Amarin Fish-Oil Drug Exclusivity.)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos